Oncology
ITEKANIL® New
Nilotinib
- INN
- Nilotinib
- Composition
- 200 mg nilotinib (as hydrochloride monohydrate) per film-coated tablet
- Therapeutic class
- Antineoplastic and immunomodulating agents
- Dosage form
- Film-coated tablet
- Schedule
- Schedule A
- Shelf life & storage
- 24 months — store below 30 °C
- MA date
- 19/11/2025
Therapeutic indication
ITEKANIL® is indicated for the treatment of patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML) in chronic or accelerated phase, with resistance or high toxicity on prior imatinib therapy.
Source: summary of product characteristics (SmPC), section 4.1.
Presentations
| Presentation | Strength | Pack | Blister | MA number |
|---|---|---|---|---|
| ITEKANIL® 200 mg | 200 mg | Box of 30 tablets | ALU/PVC-PVDC blister | 9453071H |
Prescription-only medicine. The information on this page is intended for healthcare professionals and does not replace the summary of product characteristics (SmPC) or the package leaflet.
Catalogue
